In an exchange filing, Emcure said it is the first Indian company to exclusively distribute and commercialise Poviztra, positioned as a second brand of Novo Nordisk’s semaglutide for weight management. The drug will be available across India in a once-per-week pen device in five dosage strengths, with prices starting at ₹8,790 per month for four weekly doses.
